{"id":"W2902706178","doi":"10.1016/s1470-2045(18)30788-5","title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","year":2018,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":548,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Obinutuzumab; Ibrutinib; Chlorambucil; Medicine; Oncology; Internal medicine; Open label; Chronic lymphocytic leukemia; Venetoclax; Clinical trial; Leukemia; Chemotherapy; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001769183,0.0006341409,0.002968328,0.0002812369,0.0002691044,0.00006260517,0.001308901,0.0005341711,0.001030307],"category_scores_gemma":[0.001196867,0.0004364389,0.0002367173,0.0008621822,0.001541097,0.0001737264,0.0005896101,0.0004590179,0.0004142956],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.4727633,"about_ca_system_score_gemma":0.136178,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01336656,"about_ca_topic_score_gemma":0.009103237,"domain_scores_codex":[0.9944673,0.0007188064,0.001432905,0.0009766138,0.000732629,0.001671737],"domain_scores_gemma":[0.9941512,0.002655026,0.0006021512,0.001886903,0.0003308876,0.0003738612],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9694715,0.001213591,0.000002389555,0.0003030658,0.0006738472,0.001063339,0.004450598,0.001169801,0.0006658924,0.0002399275,0.003035059,0.01771097],"study_design_scores_gemma":[0.7049532,0.03965658,0.000003436101,0.0001957912,0.0004312973,0.0002581363,0.0003088064,0.2162862,0.002762059,0.00005156614,0.03480954,0.0002834663],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9748964,0.002162675,0.00004799807,0.0008890608,0.002007762,0.008868285,0.00008194969,0.0001074496,0.01093838],"genre_scores_gemma":[0.9893438,0.002786986,0.0003868274,0.0002749316,0.003709502,0.00119658,0.0001425422,0.0000967025,0.002062127],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3365853,"threshold_uncertainty_score":0.9998829,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1690966730335881,"score_gpt":0.4438783636128727,"score_spread":0.2747816905792846,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}